A Controlled Trial of Renal Denervation for Resistant Hypertension
Top Cited Papers
- 10 April 2014
- journal article
- research article
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 370 (15), 1393-1401
- https://doi.org/10.1056/nejmoa1402670
Abstract
Prior unblinded studies have suggested that catheter-based renal-artery denervation reduces blood pressure in patients with resistant hypertension. We designed a prospective, single-blind, randomized, sham-controlled trial. Patients with severe resistant hypertension were randomly assigned in a 2:1 ratio to undergo renal denervation or a sham procedure. Before randomization, patients were receiving a stable antihypertensive regimen involving maximally tolerated doses of at least three drugs, including a diuretic. The primary efficacy end point was the change in office systolic blood pressure at 6 months; a secondary efficacy end point was the change in mean 24-hour ambulatory systolic blood pressure. The primary safety end point was a composite of death, end-stage renal disease, embolic events resulting in end-organ damage, renovascular complications, or hypertensive crisis at 1 month or new renal-artery stenosis of more than 70% at 6 months. A total of 535 patients underwent randomization. The mean (±SD) change in systolic blood pressure at 6 months was −14.13±23.93 mm Hg in the denervation group as compared with −11.74±25.94 mm Hg in the sham-procedure group (P<0.001 for both comparisons of the change from baseline), for a difference of −2.39 mm Hg (95% confidence interval [CI], −6.89 to 2.12; P=0.26 for superiority with a margin of 5 mm Hg). The change in 24-hour ambulatory systolic blood pressure was −6.75±15.11 mm Hg in the denervation group and −4.79±17.25 mm Hg in the sham-procedure group, for a difference of −1.96 mm Hg (95% CI, −4.97 to 1.06; P=0.98 for superiority with a margin of 2 mm Hg). There were no significant differences in safety between the two groups. This blinded trial did not show a significant reduction of systolic blood pressure in patients with resistant hypertension 6 months after renal-artery denervation as compared with a sham control. (Funded by Medtronic; SYMPLICITY HTN-3 ClinicalTrials.gov number, NCT01418261.)Keywords
This publication has 25 references indexed in Scilit:
- Renal Sympathetic Denervation Therapy for Resistant HypertensionCirculation: Cardiovascular Interventions, 2013
- The promise of renal denervationCleveland Clinic Journal of Medicine, 2012
- Catheter‐Based Renal Denervation for Resistant Hypertension: Rationale and Design of the SYMPLICITY HTN‐3 TrialClinical Cardiology, 2012
- Addition of Spironolactone in Patients With Resistant Arterial Hypertension (ASPIRANT)Hypertension, 2011
- Divergent Results Using Clinic and Ambulatory Blood PressuresHypertension, 2010
- Resistant Hypertension: Diagnosis, Evaluation, and TreatmentHypertension, 2008
- Recruitment to a Clinical Trial Improves Glycemic Control in Patients With DiabetesDiabetes Care, 2007
- A Blinded, Randomized, Placebo-Controlled Trial of Percutaneous Laser Myocardial Revascularization to Improve Angina Symptoms in Patients With Severe Coronary DiseaseJournal of the American College of Cardiology, 2005
- Recommendations for Blood Pressure Measurement in Humans and Experimental AnimalsCirculation, 2005